Article Figures & Data
Figures
- Figure 1.
PREVAIL Trial Design
ADT=androgen deprivation therapy; OS=overall survival; rPFS=radiographic progression-free survival.
*Total alpha=0.05, 2-sided (OS allocation=0.049; rPFS allocation=0.001); target hazard ratio: OS=0.82, rPFS=0.57.
Reproduced with permission from A Armstrong, MD.
Tables
Tools
Safety and Efficacy of Enzalutamide in Men with Metastatic Prostate Cancer: The PREVAIL Trial
Permalink:
Table of contents
Cited By...
- No citing articles found.